Prepared Statement of the Federal Trade Commission On Pharmaceutical Industry
Date
By
Timothy J. Muris, Former Chairman
File
Testimony
(183.84 KB)
Displaying 1341 - 1360 of 1586
Wrongful "Orange Book" Listing Raises Red Flag with FTC; Leads to Consent Order with Biovail Corp. Concerning its Drug Tiazac
Date
The Federal Trade Commission today announced its first complaint against - and consent order with - a pharmaceutical manufacturer for allegedly illegally acquiring an exclusive patent license and...
Public Statement
The Antitrust Implications of "Clinical Integration:" An Analysis of FTC Staff's Advisory Opinion to MedSouth
Date
This article is based on a speech delivered at the Saint Louis University Health Law Symposium on April 12, 2002, and is published in issue 47:2 of the Saint Louis University Law Journal, at page 217.
Napa Valley OB/GYN Group Settles FTC Antitrust Charges
Date
A doctors' group consisting of virtually every obstetrician and gynecologist (OB/GYN) with active medical staff privileges at the two general acute care hospitals in Napa County, California, and its...
FTC Staff Opposes Alaska Physicians' Health Plan Legislation:
Date
The staff of the Federal Trade Commission recently told the Alaska House of Representatives' Committee on Labor and Commerce that legislation authorizing collective bargaining among the state's...
Staff Advisory Opinion:
Date
Staff of the Federal Trade Commission has advised MedSouth, Inc., a multi-specialty physician practice association that includes competing primary care and specialist physicians who practice in the...
FTC Agreement with American Home Products Corp. Would Protect Consumers from Anticompetitive Practices
Date
The Federal Trade Commission today announced a consent agreement with American Home Products Corporation (AHP) that would settle charges that the company entered into an anticompetitive agreement with...
Roche Holding Ltd, In the Matter of
Roche agreed to divest, certain assets in the U.S. and Canada to settle antitrust concerns stemming from its proposed acquisition of Corange Limited. The consent order permits the acquisition but requires the divestiture of Cardiac thrombolytic agents (drugs used to treat heart attack victims) and ongoing business assets relating to chemicals used to test for the presence of illegal or abused drugs.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
9710103
Docket Number
C-3809
FTC Staff Opposes Washington State Proposal to Allow Physician Collective Bargaining
Date
A bill introduced in the Washington state legislature that seeks to authorize competing physicians, and other providers, to engage in collective bargaining with health plans over a variety of contract...
FTC Staff Opposes Alaska Proposal to Allow Physician Collective Bargaining
Date
A bill pending before the Alaska legislature that seeks to authorize competing physicians to engage in collective bargaining with health plans over fees and other terms would significantly increase...
Announced Actions for January 9, 2002
Date
The FTC has approved the issuance of two briefs, both of which are available on the Commission's Web site. The briefs were filed with respect to litigation involving: 1) Bristol-Myers-Squibb and...
In re: Buspirone Antitrust Litigation MDL
Date
Citation Number
Docket No. 1410
Amicus brief for the Federal Trade Commission, supporting argument of generic drug manufacturer that allegedly wrongful listing of patents in the FDA's "Orange Book" is not immune from antitrust...
File
In re: Buspirone Antitrust Litigation
(81.59 KB)
In re: First Databank Antitrust Litigation
Date
Citation Number
1:01CV00879
Federal Trade Commission memorandum as amicus curiae (in the alternative to motion to intervene) to oppose grant of fees to private class action counsel, where much of the consumer recovery at issue...
File
In re: First Databank Antitrust Litigation
(51.55 KB)
Non-profit Institutions Act Covers Pharmaceuticals Dispensed to Retired Employees, FTC Staff Advises
Date
Staff of the Federal Trade Commission have advised the Connecticut Hospital Association (CHA) that the Non-Profit Institutions Act covers pharmaceuticals that its member hospitals dispense to their...
Hearst Corp. To Disgorge $19 Million and Divest Business to Facts and Comparisons to Settle FTC Complaint
Date
The Federal Trade Commission today announced a proposed settlement with Hearst Corporation (Hearst) that would resolve charges that Hearst unlawfully acquired J.B. Laughery, Inc., which included the...
Hearst Trust, The, The Hearst Corporation, and First DataBank, Inc.
The Commission negotiated an agreement with The Hearst Corporation (Hearst) to settle a permanent injunction action filed by the FTC alleging that Hearst failed to provide documents required by premerger notification law and then consummated a merger that monopolized the integrated drug information database market. Under the terms of the order, Hearst divested the Medi-Span business to Lippincott Williams & Wilkins, Inc. , a subsidiary of Wolters Kluwer, n.v., disgorged $19 million in profits, and to complied with certain other obligations.
Type of Action
Federal
Last Updated
FTC Matter/File Number
9910323a
Statement of Susan A. Creighton, Deputy Director, Bureau of Competition Regarding FTC Settlement with Hearst Corporation
Date
The staff of the Federal Trade Commission has negotiated an agreement with The Hearst Corporation (Hearst), which staff will propose to the Commission as a way to settle a permanent injunction action...
Report
Staff Summary of Federal Trade Commission Activities Affecting Older Americans: January 1999-August 2001: A Commission Staff Report to the United States Senate Special Committee on Aging
Date
The Federal Trade Commission is the federal government's principal consumer protection agency, with broad jurisdiction extending over nearly the entire economy, including business and consumer...
Prepared Statement of the Federal Trade Commission On Competition in the Pharmaceutical Marketplace
Date
By
Molly S. Boast, Former Director, Bureau of Competition
File
Testimony
(157.83 KB)
Public Statement
Antitrust Issues in the Settlement of Pharmaceutical Patent Disputes, Part II
Date
As the title indicates, the settlement of pharmaceutical patent disputes is a subject that I have already addressed. (1) You may wonder why I am visiting it again. When I first discussed the issue...
Displaying 1341 - 1360 of 1586